| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,594 |
8,883 |
$3.51M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
16,472 |
16,025 |
$3.23M |
| 80053 |
Comprehensive metabolic panel |
7,523 |
6,739 |
$199K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,345 |
2,119 |
$176K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,086 |
4,434 |
$61K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,107 |
731 |
$61K |
| 70450 |
Computed tomography, head or brain; without contrast material |
793 |
703 |
$41K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
883 |
728 |
$41K |
| 71045 |
Radiologic examination, chest; single view |
3,930 |
3,617 |
$40K |
| 87070 |
|
1,655 |
1,635 |
$31K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,673 |
2,290 |
$30K |
| 85027 |
|
10,129 |
8,625 |
$29K |
| 81003 |
|
7,370 |
6,919 |
$26K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,287 |
2,256 |
$23K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,386 |
1,338 |
$19K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
157 |
151 |
$18K |
| 87420 |
|
603 |
595 |
$17K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
214 |
194 |
$16K |
| G0383 |
Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) |
37 |
28 |
$14K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,180 |
883 |
$11K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
907 |
893 |
$9K |
| 84703 |
|
1,339 |
1,262 |
$8K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
77 |
72 |
$7K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
555 |
542 |
$5K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
118 |
115 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
221 |
212 |
$5K |
| 84484 |
|
1,472 |
1,073 |
$5K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
118 |
115 |
$4K |
| S3620 |
Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) |
96 |
87 |
$4K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
455 |
394 |
$3K |
| 82016 |
|
124 |
115 |
$2K |
| 81025 |
|
307 |
291 |
$2K |
| 59025 |
Fetal non-stress test |
80 |
72 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
84 |
74 |
$2K |
| 84702 |
|
235 |
203 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
37 |
31 |
$2K |
| 83690 |
|
1,233 |
1,131 |
$2K |
| 82128 |
|
124 |
115 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
89 |
84 |
$1K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,467 |
1,226 |
$1K |
| 85730 |
|
1,176 |
1,020 |
$638.56 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
663 |
469 |
$555.52 |
| 82248 |
|
646 |
588 |
$525.71 |
| 85610 |
|
1,305 |
1,114 |
$523.32 |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
13 |
12 |
$360.68 |
| 83880 |
|
260 |
239 |
$301.40 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
146 |
111 |
$208.34 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
13 |
12 |
$194.78 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
110 |
96 |
$151.43 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
602 |
349 |
$143.15 |
| 86901 |
|
161 |
145 |
$141.92 |
| 86900 |
|
162 |
145 |
$141.92 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
257 |
175 |
$125.23 |
| 83735 |
|
690 |
532 |
$104.87 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
882 |
710 |
$31.95 |
| 87040 |
|
69 |
48 |
$26.01 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
159 |
104 |
$22.79 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
40 |
24 |
$10.06 |
| 83605 |
|
158 |
133 |
$9.72 |
| J3490 |
Unclassified drugs |
13 |
13 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
14 |
12 |
$0.00 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
65 |
63 |
$0.00 |